Patents by Inventor Keren SINIK

Keren SINIK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
    Patent number: 12252547
    Abstract: Affinity binding entities having TCRL binding domain and methods of their use are provided. More specifically these compositions bind HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP or HLA-A2/TyrD+ cells and as such can be used in diagnostics and therapy.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: March 18, 2025
    Assignee: ADICET THERAPEUTICS, INC.
    Inventors: Mira Peled Kamar, Galit Denkberg, Yoram Reiter, Ilan Beer, Keren Sinik, Yael Teboul (Elbaz), Yael Shperber (Sery), Reut Erel Segal, Ravit Oren, Dror Shmuel Alishekevitz
  • Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof
    Patent number: 11485785
    Abstract: Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: November 1, 2022
    Inventors: Aya Jakobovits, Orit Foord, Daulet Kadyl Satpayev, Mira Peled Kamar, Galit Denkberg, Yoram Reiter, Ilan Beer, Keren Sinik, Yael Teboul (Elbaz), Yael Shperber (Sery), Reut Erel Segal, Ravit Oren, Dror Shmuel Alishekevitz
  • AFFINITY ENTITIES COMPRISING A TCR-LIKE ANTIBODY BINDING DOMAIN WITH HIGH AFFINITY AND FINE SPECIFICITY AND USES OF SAME
    Publication number: 20210388111
    Abstract: Affinity binding entities having TCRL binding domain and methods of their use are provided. More specifically these compositions bind HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP or HLA-A2/TyrD+ cells and as such can be used in diagnostics and therapy.
    Type: Application
    Filed: May 11, 2021
    Publication date: December 16, 2021
    Inventors: Mira PELED KAMAR, Galit DENKBERG, Yoram REITER, Ilan BEER, Keren SINIK, Yael TEBOUL (ELBAZ), Yael SHPERBER (SERY), Reut EREL SEGAL, Ravit OREN, Dror Shmuel ALISHEKEVITZ
  • Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
    Patent number: 11001642
    Abstract: Affinity binding entities having TCRL binding domain and methods of their use are provided. More specifically these compositions bind HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP or HLA-A2/TyrD+ cells and as such can be used in diagnostics and therapy.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: May 11, 2021
    Inventors: Mira Peled Kamar, Galit Denkberg, Yoram Reiter, Ilan Beer, Keren Sinik, Yael Teboul (Elbaz), Yael Shperber (Sery), Reut Erel Segal, Ravit Oren, Dror Shmuel Alishekevitz
  • ANTIBODIES CAPABLE OF BINDING HLA-A2/TYRD IN AN HLA RESTRICTED MANNER AND USES THEREOF
    Publication number: 20200207858
    Abstract: Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.
    Type: Application
    Filed: June 14, 2017
    Publication date: July 2, 2020
    Inventors: Aya Jakobovits, Orit FOORD, Daulet Kadyl Satpayev, Mira Peled Kamar, Galit Denkberg, Yoram Reiter, Ilan Beer, Keren Sinik, Yael Teboul (Elbaz), Yael Shperber (Sery), Reut Erel Segal, Ravit Oren, Dror Shmuel Alishekevitz
  • T CELL RECEPTOR LIKE ANTIBODIES HAVING FINE SPECIFICITY
    Publication number: 20180179283
    Abstract: An antibody capable of binding, with a human major histocompatibility complex (MHC)-restricted specificity, a MHC being complexed with an HLA-restricted peptide antigen is provided. The antibody having a binding specificity dictated by at least 4 amino acid residues in said HLA-restricted peptide such that at least 70% reduction in binding of said antibody to said complex is observed when each of said at least 4 amino acid residues is substituted as determined by FACS of cells loaded with said HLA-restricted peptide comprising said substitution, said at least 4 amino acid residues not being anchor residues.
    Type: Application
    Filed: June 8, 2016
    Publication date: June 28, 2018
    Inventors: Mira PELED KAMAR, Galit DENKBERG, Yoram REITER, Ilan BEER, Keren SINIK, Yael TEBOUL (ELBAZ), Yael SHPERBER (SERY), Reut EREL SEGAL, Ravit OREN, Dror Shmuel ALISHEKEVITZ
  • AFFINITY ENTITIES COMPRISING A TCR-LIKE ANTIBODY BINDING DOMAIN WITH HIGH AFFINITY AND FINE SPECIFICITY AND USES OF SAME
    Publication number: 20180171024
    Abstract: Affinity binding entities having TCRL binding domain and methods of their use are provided. More specifically these compositions bind HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP or HLA-A2/TyrD+ cells and as such can be used in diagnostics and therapy.
    Type: Application
    Filed: June 8, 2016
    Publication date: June 21, 2018
    Inventors: Mira PELED KAMAR, Galit DENKBERG, Yoram REITER, IIan BEER, Keren SINIK, Yael TEBOUL (ELBAZ), Yael SHPERBER (SERY), Reut EREL SEGAL, Ravit OREN, Dror Shmuel ALISHEKEVITZ